# Apollomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apollomics-2

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.apollomics.com
- Latest round: Series B (Jan 9, 2026)
- Investors on record: 1

## About

Founded in 2016 and headquartered in Nanjing, China, Nanjing Apollomics Biotech Inc. focuses on developing innovative biochemical products. The company has not undergone any noted pivots or changes in its business strategy since its inception. The founder's history and details on other companies are not publicly available. In January 2026, Apollomics raised Series B funding led by new investor Green Pine Capital Partners.
Apollomics' primary offerings revolve around a comprehensive range of biochemical products designed for protein quantification and analysis. Their core products include stable isotope-labeled internal standards, amino acids, hormones, therapeutic drugs, and various assays for water-soluble and fat-soluble vitamins. These products serve critical applications in clinical diagnostics, pharmaceutical research, and nutrition science, helping laboratories and researchers accurately measure biomolecules in various samples. The company's clientele includes academic institutions, research organizations, and biotechnology firms across global markets such as North America, Europe, and Asia, where they address the growing need for precise analytical tools in life sciences.
Apollomics generates revenue through a structure that primarily focuses on B2B transactions with research institutions and pharmaceutical companies. Their sales model includes direct sales of products and potential partnership agreements with research entities. Revenue streams are diversified across their flagship product lines, which include proprietary assays and stable isotope standards that cater to specific research needs. The pricing strategy is tailored to reflect the specialized nature of their offerings, ensuring that clients receive high-quality, scientifically validated products. These transactions typically involve bulk orders that facilitate long-term collaborations, allowing customers access to essential resources for ongoing research and development projects.

## Funding rounds

- Series B, Jan 9, 2026 — Green Pine Capital Partners

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B